Hur kan du hjälpa dina patienter nå sina glykemiska målvärden.





SE-NON-00327 10/2020 26 oktober 2020.



Referenser

  • 1.

    Khunti K, Seidu S. Therapeutic inertia and the legacy of dysglycemia on the microvascular and macrovascular complications of diabetes. Diabetes Care. 2019;42(3):349–351.

  • 2.

    Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care 2019;42:416–426.

  • 3.

    De Pablos-Velasco P, Parhofer KG, Bradley C, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf). 2014;80:47–56.

  • 4.

    Pantalone KM, Misra-Hebert AD, Hobbs TM, et al. Clinical inertia in type 2 diabetes management: evidence from a large, real-world data set. Diabetes Care. 2018;41(7):e113-e114.

  • 5.

    Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes Obes Metab. 2018;20:427-437.

  • 6.

    Fernandes G, Sawhney B, Hannachi H, et al. Distance to glycemic goal at the time of treatment intensification in patients with type 2 diabetes mellitus failing metformin monotherapy in the United States. Curr Med Res Opin. 2020:1-8.

  • 7.

    Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43(6):501-511.

  • 8.

    Abbatecola AM, Spazzafumo L, Fabbietti P, et al. Diabetes-related quality of life is enhanced by glycaemic improvement in older people. Diabet. Med. 2015;32:243–249.

  • 9.

    Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.